Feline Protein-Losing Enteropathy

Feline Protein-Losing Enteropathy (PLE) is a clinical syndrome in cats characterized by excessive loss of serum proteins—primarily albumin and globulins—through a diseased gastrointestinal tract. Unlike dogs, in which PLE is relatively well-characterized as a distinct diagnosis, cats more commonly develop protein loss secondary to underlying intestinal diseases such as inflammatory bowel disease (IBD), intestinal lymphoma, or severe parasitic infections. The resulting hypoalbuminemia leads to reduced oncotic pressure and a cascade of systemic complications including ascites, pleural effusion, and peripheral edema. PLE is considered a serious condition in cats and demands thorough diagnostic workup to identify and address the primary underlying cause.

Primary Causes:

Feline PLE is almost always secondary to an underlying intestinal or systemic disease rather than a primary protein-losing disorder in itself. The most common underlying etiologies include:

1. ·

   Inflammatory Bowel Disease (IBD): Chronic lymphocytic-plasmacytic, eosinophilic, or mixed enteritis disrupts the normal mucosal barrier. Villous atrophy, crypt changes, and mucosal inflammation impair both absorptive capacity and mucosal integrity, allowing protein-rich lymph and plasma to leak into the intestinal lumen.

2. ·

   Gastrointestinal Lymphoma: Small-cell (low-grade) lymphoma is particularly prevalent in older cats and is one of the most important differentials alongside IBD. Large-cell lymphoma, though less common, carries a more aggressive course. Neoplastic infiltration of the intestinal wall disrupts the epithelial barrier and lymphatic drainage.

3. ·

   Intestinal Lymphangiectasia: Though rare in cats compared to dogs, dilation and dysfunction of intestinal lacteals leads to leakage of protein-rich lymph directly into the intestinal lumen. Obstruction or abnormal development of lymphatic vessels underlies this form.

4. ·

   Severe Parasitism: Heavy burdens of Tritrichomonas foetus, Giardia spp., or strongylid nematodes can damage the intestinal epithelium and contribute to protein loss, particularly in young or immunocompromised cats.

5. ·

   Fungal Infections: Pythiosis or histoplasmosis causing granulomatous enteritis can destroy large areas of intestinal mucosa.

Pathophysiological Mechanism:

Under normal circumstances, proteins that enter the intestinal lumen are digested and reabsorbed as amino acids. In PLE, the rate of protein extravasation exceeds the liver's synthetic capacity. Three main mechanisms are at play:

• ·Mucosal erosion or ulceration: Direct disruption of the intestinal epithelial barrier allows plasma proteins to leak through.
• ·Increased mucosal permeability without ulceration: Severe inflammation alters tight junction integrity, enabling transudation of proteins across the intact but functionally compromised epithelium.
• ·Lymphatic obstruction or dilation: Impaired lymphatic flow causes protein-rich lymph to back-leak into the intestinal lumen (lymphangiectasia pattern).

The resulting hypoalbuminemia (serum albumin commonly < 2.0 g/dL, often < 1.5 g/dL in severe cases) reduces intravascular oncotic pressure. Fluid shifts from the intravascular compartment into body cavities and interstitial spaces (third spacing), producing ascites, pleural effusion, and edema. Hypoglobulinemia frequently accompanies hypoalbuminemia in PLE, distinguishing this from hepatic synthetic failure (which can cause selective hypoalbuminemia with normal or elevated globulins) and from protein-losing nephropathy (in which globulins are typically preserved because renal glomeruli selectively lose smaller albumin molecules).

Diagnosis of feline PLE requires a systematic approach to confirm protein loss through the gastrointestinal tract, exclude other causes of hypoproteinemia, and—critically—identify the underlying disease.

History and Physical Examination: A thorough history of chronic GI signs combined with physical findings of weight loss, palpable intestinal thickening, abdominal fluid wave (ballottement), or muffled heart/lung sounds raises strong clinical suspicion.

Laboratory Evaluation:

Serum Biochemistry Panel:

• ·Albumin (ALB): LOW — The hallmark finding; values < 2.0 g/dL are typical; severe cases may fall below 1.0 g/dL. This is the single most important marker.
• ·Total Protein (TP): LOW — Reflects both albumin and globulin loss.
• ·Globulin (GLOB): LOW or normal — Panhypoproteinemia (both ALB and GLOB low) is characteristic of PLE and helps distinguish it from hepatic failure (where GLOB may be normal/elevated) and PLN (where GLOB is often preserved).
• ·Blood Urea Nitrogen (BUN): LOW to normal — Reduced hepatic urea synthesis due to decreased protein substrate; protein malnutrition reduces nitrogen load.
• ·Creatinine (CREA): LOW to normal — Reduced muscle mass from cachexia lowers baseline creatinine.
• ·ALT (Alanine Aminotransferase): Variable — May be mildly elevated if hepatic congestion from ascites is present, or normal; primary hepatic disease must be excluded.
• ·Total Bilirubin (TBIL): Usually normal — Elevation suggests concurrent hepatobiliary disease.
• ·Glucose: Variable — May be low if severe malabsorption is present.
• ·Calcium: Often LOW — Hypocalcemia can accompany hypoalbuminemia (ionized calcium should be measured to confirm true hypocalcemia).
• ·Cholesterol: LOW — Particularly in lymphangiectasia, where fat absorption is severely impaired; hypocholesterolemia alongside hypoalbuminemia is a strong clue.

Complete Blood Count (CBC):

• ·Hematocrit (HCT): LOW or normal — Mild to moderate anemia (often normocytic normochromic) may occur due to chronic disease, inflammation, or blood loss; however, hemoconcentration from fluid shifts can mask anemia.
• ·WBC: Variable — Lymphopenia can be seen with lymphangiectasia (loss of lymphocytes into the gut); leukocytosis may be present with inflammation or infection.
• ·Platelets (PLT): Variable — Thrombocytopenia can occur in severe inflammatory states; conversely, reactive thrombocytosis may be present.

Urinalysis with Urine Protein:Creatinine Ratio (UPC):

• ·Essential to rule out protein-losing nephropathy (PLN) as the cause of hypoalbuminemia. A UPC < 0.4 in a cat with significant hypoalbuminemia strongly supports intestinal protein loss as the primary source.

Fecal Examination:

• ·Fecal flotation and direct smear for parasites (Giardia, Tritrichomonas, nematodes).
• ·Fecal culture or PCR for enteropathogens.
• ·Fecal alpha-1 proteinase inhibitor (fecal α1-PI) assay: This is the gold-standard noninvasive test for confirming GI protein loss. Elevated fecal α1-PI confirms protein exudation into the GI tract and is highly specific for PLE. However, this test has limited availability in some regions.

Serum Cobalamin (Vitamin B12) and Folate:

• ·Cobalamin: Often LOW — Cobalamin deficiency is a common and clinically important finding in cats with significant small intestinal disease (IBD, lymphoma). It is both a marker of disease severity and a therapeutic target. Severe hypocobalaminemia independently worsens the prognosis and is associated with more severe mucosal damage.
• ·Folate: Variable — Elevated folate may suggest bacterial overgrowth/dysbiosis; low folate suggests proximal small intestinal disease.

TLI (Trypsin-Like Immunoreactivity):

• ·To rule out exocrine pancreatic insufficiency (EPI) as a co-contributor to malabsorption.

Diagnostic Imaging:

• ·Abdominal Radiography: May reveal loss of serosal detail, abdominal effusion, or intestinal gas patterns consistent with ileus.
• ·Abdominal Ultrasonography (Ultrasound — US): The most valuable imaging modality. Key findings include: intestinal wall thickening or loss of normal layering, mucosal hyperechogenicity ("striations" in the mucosa — a hyperechoic mucosal pattern strongly associated with lymphangiectasia in dogs and occasionally cats), enlarged mesenteric lymph nodes, ascites, pleural effusion, and masses. Ultrasound-guided fine-needle aspiration (FNA) of thickened bowel loops or lymph nodes can provide cytological information.
• ·Thoracic Radiography or Ultrasound: To assess for pleural effusion.

Effusion Analysis:

• ·Abdominal or pleural fluid is typically a pure transudate (total protein < 2.5 g/dL, specific gravity < 1.017, low cell count) due to reduced oncotic pressure—consistent with hypoalbuminemia-driven third spacing. Modified transudates or exudates should prompt investigation for other causes (FIP, neoplasia, septic effusion).

Tissue Biopsy (Definitive Diagnosis of Underlying Cause):

• ·Histopathology is required to definitively diagnose the primary disease causing PLE (IBD vs. lymphoma vs. lymphangiectasia, etc.).
• ·Endoscopy with biopsy (esophagogastroduodenoscopy [EGD] and colonoscopy): Preferred initial approach; allows visual assessment of mucosa and collection of multiple mucosal biopsies. Limitation: endoscopic biopsies are superficial (mucosa/submucosa only) and may miss deeper mural disease.
• ·Full-thickness surgical biopsy (laparotomy or laparoscopy): Provides full-thickness specimens including deeper mucosal layers, submucosa, and muscularis, which is essential when lymphoma is suspected but not confirmed on endoscopic biopsy, or when lymphangiectasia (which affects deeper lymphatics) needs confirmation. However, surgical risk is elevated in severely hypoalbuminemic cats due to impaired wound healing.
• ·PARR (PCR for Antigen Receptor Rearrangement): Molecular clonality testing on biopsy tissue or FNA specimens can help differentiate IBD (polyclonal) from lymphoma (monoclonal), particularly when histology is equivocal.

Treatment of feline PLE is directed at both the underlying disease and the clinical consequences of protein loss. A multimodal approach is almost always necessary.

1. Treating the Underlying Disease:

Inflammatory Bowel Disease (IBD):

• ·Dietary modification: A hydrolyzed protein diet or a novel protein diet (e.g., rabbit, venison, duck) is a cornerstone of IBD management. Highly digestible, low-fiber diets reduce antigenic stimulation and improve absorption. A dietary trial of 4–8 weeks with strict exclusion is recommended.
• ·Corticosteroids: Prednisolone (not prednisone, as cats have reduced hepatic conversion of prednisone to prednisolone) is the first-line immunosuppressive agent. Starting doses are typically 1–2 mg/kg orally every 24 hours, with gradual tapering once remission is achieved. Dexamethasone may be used short-term in cats unable to receive oral medications.
• ·Chlorambucil: A low-dose alkylating agent frequently combined with prednisolone in cats, particularly when disease is severe or refractory. A common protocol is chlorambucil 2 mg orally every other day (or pulse-dosed at 20 mg/m² every 2 weeks). The combination of prednisolone + chlorambucil is often the standard of care for both severe IBD and low-grade lymphoma.
• ·Budesonide: An enteric-release corticosteroid with high first-pass hepatic metabolism; may have fewer systemic side effects than prednisolone, though evidence in cats is more limited than in dogs.
• ·Metronidazole: Used as an adjunct for its anti-anaerobic and immunomodulatory properties; 10–15 mg/kg orally every 12–24 hours.

Gastrointestinal Lymphoma:

• ·Small-cell (low-grade) lymphoma: Typically responds very well to the oral prednisolone + chlorambucil protocol described above, with reported median survival times of 2–3 years or more in cats achieving remission.
• ·Large-cell (high-grade) lymphoma: Requires more aggressive combination chemotherapy (e.g., CHOP or COP-based protocols—cyclophosphamide, vincristine, doxorubicin, prednisolone); prognosis is considerably worse.

Lymphangiectasia:

• ·Ultra-low-fat diet: A critical intervention; dietary fat dramatically stimulates lymph flow and exacerbates lymphatic leakage. Fat intake should be minimized (<10–15% of metabolizable energy from fat); commercially available low-fat diets or home-cooked recipes under veterinary nutritionist guidance are used.
• ·Corticosteroids for anti-inflammatory and anti-lymphangiogenic effects.
• ·Medium-chain triglycerides (MCT oil): MCTs are absorbed directly via the portal vein, bypassing intestinal lacteal transport, and may supplement caloric intake without aggravating lymphangiectasia.

2. Cobalamin (Vitamin B12) Supplementation: Cobalamin supplementation is critical whenever hypocobalaminemia is documented. Cats with PLE and concurrent cobalamin deficiency will not respond adequately to treatment without correction. Cyanocobalamin is administered subcutaneously at 250 mcg per cat weekly for 6 weeks, then every other week, then monthly, with serum levels rechecked to guide ongoing supplementation. Oral cobalamin supplements are available but absorption is unreliable in cats with significant intestinal disease.

3. Nutritional Support:

• ·Highly digestible, appropriately protein-restricted (not severely limited, but high-quality, highly bioavailable protein) diets are important.
• ·Nasogastric, esophagostomy tube, or jejunostomy tube feeding may be required in severely anorexic cats to maintain caloric intake and provide amino acid substrate for albumin synthesis.
• ·Omega-3 fatty acids: May have anti-inflammatory effects, though evidence is more robust in dogs.

4. Management of Effusions:

• ·Therapeutic abdominocentesis or thoracocentesis: May be required for symptomatic relief in cats with large effusions causing discomfort or respiratory compromise. Removing effusion fluid temporarily reduces protein content further; this approach is palliative while underlying disease is being treated.
• ·Colloid support (e.g., human serum albumin, fresh frozen plasma): Colloid therapy is theoretically attractive for expanding oncotic pressure. Fresh frozen plasma (FFP) at 5–10 mL/kg IV provides albumin and clotting factors. However, the albumin increment is transient, volumes required are large, and FFP is expensive. Human albumin products can cause hypersensitivity reactions in cats and are generally used with caution only in acute, severe, life-threatening hypoalbuminemia when no alternative is available.
• ·Diuretics (furosemide): Generally avoided or used with extreme caution in PLE, as these cats are already intravascularly volume-depleted due to third-spacing; aggressive diuresis can worsen renal perfusion and electrolyte imbalances.

5. Gastroprotectants and Supportive GI Medications:

• ·Proton pump inhibitors or H2-blockers (omeprazole, famotidine) if gastric ulceration or acid-related disease is suspected.
• ·Probiotics: Growing interest in feline GI microbiome modulation; limited but emerging evidence suggests benefit as adjuncts in chronic enteropathy.
• ·Antiparasitic therapy (fenbendazole, ronidazole for Tritrichomonas) when relevant organisms are identified.

6. Anti-thrombotic Considerations: Hypoalbuminemia and protein loss can alter coagulation factor levels, and while cats are less clearly predisposed to thromboembolic complications from PLE than dogs, monitoring coagulation status (PT, PTT) is reasonable in severe cases. Low-dose aspirin or clopidogrel may be considered if thromboembolic risk is identified.

7. Monitoring:

• ·Serial serum albumin, total protein, and cobalamin levels are used to assess treatment response.
• ·Body weight and body condition score (BCS) monitoring every 2–4 weeks during initial treatment.
• ·Repeat abdominal ultrasound to monitor for resolution of effusion, improvement in intestinal wall architecture, and lymph node changes.

The prognosis for feline PLE is highly variable and is fundamentally determined by the underlying etiology rather than protein loss per se.

By Underlying Disease:

• ·

  IBD-associated PLE: Cats with IBD-driven protein loss that respond to dietary management and immunosuppression can achieve prolonged remission. Many cats with moderate IBD live for years with good quality of life with appropriate therapy. However, those presenting with severe hypoalbuminemia (albumin < 1.5 g/dL), refractory ascites, or pleural effusion carry a more guarded prognosis, and some will not respond to therapy.

• ·

  Low-grade (small-cell) gastrointestinal lymphoma: This is the most common GI tumor in cats and responds remarkably well to oral prednisolone + chlorambucil therapy. Median survival times reported in the veterinary literature are generally in the range of 18–36 months, with some cats achieving remissions of 3–4 years or longer. This form of GI lymphoma in cats is one of the more favorable oncologic diagnoses in small animal medicine.

• ·

  Large-cell (high-grade) GI lymphoma: Carries a significantly worse prognosis; even with aggressive multi-agent chemotherapy, median survival times are typically 2–6 months, and complete remissions are uncommon. Mortality associated with high-grade GI lymphoma is very high within the first year.

• ·

  Lymphangiectasia: Prognosis is guarded to fair. In cats that respond to ultra-low-fat dietary management and corticosteroids, long-term stabilization is achievable but requires lifelong strict dietary management. Refractory cases have a poor prognosis.

• ·

  Severe hypoalbuminemia at presentation (albumin < 1.0 g/dL): Regardless of underlying cause, cats presenting with profoundly low albumin levels have increased short-term mortality risk, particularly during the stabilization phase of treatment. The combination of pleural effusion with severe hypoalbuminemia worsens the immediate prognosis.

Overall Mortality Consideration: The overall mortality rate for feline PLE is difficult to state as a single number given the heterogeneous underlying causes. Based on published veterinary literature and clinical experience: cats with PLE secondary to low-grade lymphoma or IBD that receive appropriate treatment have a reasonable chance of survival measured in years; those with high-grade lymphoma or refractory severe disease have a short-term mortality rate exceeding 70–80% within 6 months. For the condition as a whole, PLE carries a significant mortality burden, with an estimated overall case-fatality rate of approximately 40–60% depending on case mix, with severe or refractory cases approaching higher end mortality.

Note: No single peer-reviewed prospective study specifically addressing mortality in feline PLE as a unified syndrome was cited in the reference literature for this entry. The figures provided reflect consensus from general veterinary internal medicine and oncology literature.

Because feline PLE is almost uniformly a consequence of underlying disease processes rather than a primary condition, true primary prevention is focused on minimizing risk factors for the causative diseases:

Parasite Control:

• ·Regular fecal examinations (at least annually, more frequently in multi-cat households or outdoor cats) and appropriate antiparasitic treatment help prevent Giardia, nematode infestations, and Tritrichomonas foetus infections that can contribute to protein-losing enteropathy, particularly in young cats.
• ·Good hygiene, avoidance of coprophagia, and prompt treatment of infected animals in multi-cat environments reduce transmission.

Diet and Environment:

• ·Feeding high-quality, balanced commercial diets reduces the risk of nutritional deficiencies that can compromise intestinal mucosal integrity.
• ·Minimizing dietary allergen exposure and avoiding frequent abrupt dietary changes may reduce the risk of developing adverse food reactions that can progress to or mimic IBD.
• ·Stress reduction (adequate space, environmental enrichment) is important given the role of chronic stress in feline gastrointestinal motility disorders and possibly in IBD pathogenesis.

Routine Veterinary Care:

• ·Regular wellness examinations (at least annually for adult cats, twice yearly for cats over 10 years) allow early detection of weight loss, hypoproteinemia, and GI abnormalities before they become severe.
• ·Routine blood work (chemistry panel with albumin) in senior cats (>10 years) is valuable for early identification of hypoalbuminemia.
• ·Early intervention in cats diagnosed with IBD—before disease becomes severe and protein-losing—may prevent the development of overt PLE.

No Vaccine: There is no vaccine available for feline PLE or for the most common underlying causes (IBD, lymphoma). Preventing feline lymphoma through FeLV vaccination in cats at risk of retroviral exposure may reduce the incidence of FeLV-associated GI lymphoma, though the majority of feline GI lymphoma cases are not FeLV-associated.

Genetic / Breed Considerations: Certain breeds, such as the Siamese and related Oriental breeds, may have increased susceptibility to intestinal lymphoma. Breeders and owners of predisposed breeds should be particularly vigilant about early signs of GI disease and should maintain close veterinary oversight as these cats age.